Feature

Podcast

Tariffs and Drug Prices: Understanding the Impact on Pharmaceuticals

Author(s):

Miranda Schmalfuhs

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

In this Pharmaceutical Executive podcast episode, UpScriptHealth founder and CEO Peter Ax discusses:

  • The impact of tariffs on the pharmaceutical industry, highlighting branded and generics medications
  • How tariffs could lead to strategic supply chain changes, including potential US manufacturing shifts
  • How digital health platforms can help potentially offset tariff impacts
  • The importance of telehealth in ensuring medication availability
  • Strategic partnerships between digital health platforms and pharma companies to improve patient care and access
  • and more

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Arda Ural
Amy Hessels, Bayer
Related Content
President Donald Trump
July 31st 2025

President Trump Issues Letters to 17 Major Pharma Companies Demanding Action on Most-Favored-Nation Order

Mike Hollan
The letter states that the companies have 60 days to meet the President's requirements.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
July 31st 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Credit: Tada Images | stock.adobe.com
July 31st 2025

IGNYTE Trial Investigators Press FDA to Reconsider Replimune CRL Amid Promising Melanoma Data, Leadership Shakeup

Davy James
Following a complete response letter rejecting accelerated approval for RP1 in advanced melanoma, IGNYTE trial investigators are urging the FDA to reevaluate the therapy’s robust survival data, just as agency leadership changes raise new questions.
Jennifer Butler
July 31st 2025

The Misinformation Maze: Navigating Public Health in the Digital Age

Miranda Schmalfuhs
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Vinay Prasad Out as FDA CBER Head
July 31st 2025

Vinay Prasad Out as FDA CBER Head

PharmExec Staff
Vinay Prasad, MD, MPH, departs FDA's Center for Biologics, citing family time and avoiding distraction.
US and EU Finalize Trade Agreement with Pharma Tariffs in Focus
July 31st 2025

US and EU Finalize Trade Agreement with Pharma Tariffs in Focus

Nicholas Saraceno, Editor
The pact introduces a 15% levy on most EU exports, including pharmaceuticals.